Skip to main content
Erschienen in: Rheumatology International 9/2013

01.09.2013 | Short Communication

Serum levels of selected chemokines in systemic lupus erythematosus patients

verfasst von: Eugeniusz Hrycek, Andrzej Franek, Edward Błaszczak, Justyna Dworak, Antoni Hrycek

Erschienen in: Rheumatology International | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Chemokines promote leukocyte traffic into the site of inflammation. Serum levels of monocyte chemotactic protein 1 (MCP-1), stromal cell-derived factor-1 (SDF-1), interferon-gamma-inducible protein 10 (IP-10), and interleukin-8 (IL-8) were evaluated in 48 treated women with systemic lupus erythematosus (SLE) and mild-to-moderate disease severity. The results were compared between the whole SLE group and the control (29 women). The relationships between chemokines, their concentrations, and peripheral blood leukocyte count and between the chemokines and individual leukocyte populations (polymorphonuclear leukocytes—PMNs, lymphocytes—Ls, monocytes—Ms, eosinophils) counts were determined. The relationships between the analyzed chemokines were also determined in the control. SLE subjects had significantly higher MCP-1, SDF-1, IP-10, and lower IL-8 concentrations compared to the control. Moderate, positive correlations between MCP-1/SDF-1, SDF-1/IP-10 and a negative correlation between MCP-1/IL8 were observed in the patient group. Moderate, negative correlations were found between SDF-1/total leukocyte count, SDF-1/absolute number of PMNs as well as between IP-10/total leukocyte count, IP-10/absolute PMNs, Ls, and Ms counts in peripheral blood of SLE group. We suggest that the obtained results and correlations observed between the examined parameters might be used to monitor SLE course and progression. However, further randomized clinical studies should be carried out on in untreated and treated patients with SLE.
Literatur
1.
Zurück zum Zitat Kong KO, Tan AW, Thong BYH, Lian TY, Cheng YK, Teh CL, Koh ET, Chng HH, Lau TC, Leong KR, Leung BP, Howe HS (2009) Enhanced expression of interferon-inducible protein -10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 156:134–140PubMedCrossRef Kong KO, Tan AW, Thong BYH, Lian TY, Cheng YK, Teh CL, Koh ET, Chng HH, Lau TC, Leong KR, Leung BP, Howe HS (2009) Enhanced expression of interferon-inducible protein -10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol 156:134–140PubMedCrossRef
2.
Zurück zum Zitat Hrycek A, Pochopień-Kenig G, Ścieszka J (2007) Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 40:217–222PubMedCrossRef Hrycek A, Pochopień-Kenig G, Ścieszka J (2007) Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 40:217–222PubMedCrossRef
3.
Zurück zum Zitat Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Tekehara K, Sato S (2003) Serum concentrations of the CXC chemokines Interleukin 8 and Growth-Regulated Oncogene-α are elevated in patients with systemic sclerosis. J Rheumatol 30:1524–1528PubMed Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Tekehara K, Sato S (2003) Serum concentrations of the CXC chemokines Interleukin 8 and Growth-Regulated Oncogene-α are elevated in patients with systemic sclerosis. J Rheumatol 30:1524–1528PubMed
4.
Zurück zum Zitat Kaneko H, Ogasawara H, Naito T, Akimoto H, Hishikawa T, Lee S, Segikawa I, Tokano Y, Takasaki Y, Hirose S-I, Hashimoto H (1999) Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol 26:568–573PubMed Kaneko H, Ogasawara H, Naito T, Akimoto H, Hishikawa T, Lee S, Segikawa I, Tokano Y, Takasaki Y, Hirose S-I, Hashimoto H (1999) Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol 26:568–573PubMed
5.
Zurück zum Zitat Wang A, Guilpain Ph, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst AM, Boudreaux Ch, Roux Ch, Wakeland EK, Davis LS, Batteux F, Mohan Ch (2010) Dysregulated expression of CXCR4/CXCL12 in subset of patients with systemic lupus erythematosus. Arthritis Rheum 62:3436–3446PubMedCrossRef Wang A, Guilpain Ph, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ, Lin F, Fairhurst AM, Boudreaux Ch, Roux Ch, Wakeland EK, Davis LS, Batteux F, Mohan Ch (2010) Dysregulated expression of CXCR4/CXCL12 in subset of patients with systemic lupus erythematosus. Arthritis Rheum 62:3436–3446PubMedCrossRef
6.
Zurück zum Zitat Chong BF, Mohan Ch (2009) Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 13:1147–1153PubMedCrossRef Chong BF, Mohan Ch (2009) Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 13:1147–1153PubMedCrossRef
7.
Zurück zum Zitat Ye DQ, Hu YS, Li XP, Yang SG, Hao JH, Hung F, Zhang XJ (2005) The correlation between monocyte chemoattractant protein-1 and the arthritis of systemic lupus erythematosus among Chinese. Arch Dermatol Res 296:366–371PubMedCrossRef Ye DQ, Hu YS, Li XP, Yang SG, Hao JH, Hung F, Zhang XJ (2005) The correlation between monocyte chemoattractant protein-1 and the arthritis of systemic lupus erythematosus among Chinese. Arch Dermatol Res 296:366–371PubMedCrossRef
8.
Zurück zum Zitat Alzawawy A, Zohary M, Ablordiny M, Eldalie M (2009) Estimation on monocyte-chemoattractant protein-1 (Mcp-1) level in patients with lupus nephritis. Intern J Rheum Dis 12:311–318CrossRef Alzawawy A, Zohary M, Ablordiny M, Eldalie M (2009) Estimation on monocyte-chemoattractant protein-1 (Mcp-1) level in patients with lupus nephritis. Intern J Rheum Dis 12:311–318CrossRef
9.
Zurück zum Zitat Lima G, Soto-Vega E, Atisha-Fregoso Y, Sánchez-Guerrero J, Vallejo M, Vargas-Alarcón G, Liorente L (2007) MCP-1, RANTES, and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Human Immunol 68:980–985CrossRef Lima G, Soto-Vega E, Atisha-Fregoso Y, Sánchez-Guerrero J, Vallejo M, Vargas-Alarcón G, Liorente L (2007) MCP-1, RANTES, and SDF-1 polymorphisms in Mexican patients with systemic lupus erythematosus. Human Immunol 68:980–985CrossRef
10.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
11.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
12.
Zurück zum Zitat Suzuki M, Hashizume M, Yoshida H, Mihara M (2010) Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30:309–315PubMedCrossRef Suzuki M, Hashizume M, Yoshida H, Mihara M (2010) Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30:309–315PubMedCrossRef
13.
Zurück zum Zitat Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, von Feldt JM (2007) Monocyte chemoattractant protein-1: plasma concentration and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740–746PubMed Brown KS, Nackos E, Morthala S, Jensen LE, Whitehead AS, von Feldt JM (2007) Monocyte chemoattractant protein-1: plasma concentration and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 34:740–746PubMed
14.
Zurück zum Zitat Lit LCW, Wong CK, Tam LS, Li EKM, Lam CWK (2006) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65:209–215PubMedCrossRef Lit LCW, Wong CK, Tam LS, Li EKM, Lam CWK (2006) Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 65:209–215PubMedCrossRef
15.
Zurück zum Zitat Bauer JW, Petri M, Batliwalla FM, Koeuth Th, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098–3107PubMedCrossRef Bauer JW, Petri M, Batliwalla FM, Koeuth Th, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60:3098–3107PubMedCrossRef
16.
Zurück zum Zitat Robak E, Kulczycka L, Sysa-Jędrzejowska A, Wierzbowska A, Robak T (2007) Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 18:9–15 Robak E, Kulczycka L, Sysa-Jędrzejowska A, Wierzbowska A, Robak T (2007) Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 18:9–15
17.
Zurück zum Zitat Narumi S, Takeuchi T, Kobayashi Y, Konishi K (2000) Serum levels of IFN- inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12:1561–1565PubMedCrossRef Narumi S, Takeuchi T, Kobayashi Y, Konishi K (2000) Serum levels of IFN- inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 12:1561–1565PubMedCrossRef
18.
Zurück zum Zitat Szekanecz Z, Szücs G, Szántó S, Koch AE (2006) Chemokines in rheumatic diseases. Curr Drug Targets 7:91–102PubMedCrossRef Szekanecz Z, Szücs G, Szántó S, Koch AE (2006) Chemokines in rheumatic diseases. Curr Drug Targets 7:91–102PubMedCrossRef
19.
Zurück zum Zitat Hsich S-C, Wu T-H, Tsai C-Y, Li K-J, Lu M-C, Wu C-H, Yu C-L (2008) Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus. Rheumatology 47:150–157CrossRef Hsich S-C, Wu T-H, Tsai C-Y, Li K-J, Lu M-C, Wu C-H, Yu C-L (2008) Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus. Rheumatology 47:150–157CrossRef
20.
Zurück zum Zitat Link DC (2005) Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res 32:169–178PubMedCrossRef Link DC (2005) Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol Res 32:169–178PubMedCrossRef
21.
Zurück zum Zitat Klebanoff SJ, Clark BA (1978) The neutrophil: function and clinical disorders. North-Holland, Amsterdam Klebanoff SJ, Clark BA (1978) The neutrophil: function and clinical disorders. North-Holland, Amsterdam
22.
Zurück zum Zitat Matamoros MC, Walker BK, Van Dyke K, Van Dyke CJ (1983) Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes. Pharmacology 27:29–39PubMedCrossRef Matamoros MC, Walker BK, Van Dyke K, Van Dyke CJ (1983) Effect of cancer chemotherapeutic agents on the chemiluminescence of human granulocytes. Pharmacology 27:29–39PubMedCrossRef
23.
Zurück zum Zitat Kotulová D, Stefanovic J (1983) Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone. J Hyg Epidemiol Microbiol Immunol 27:253–257PubMed Kotulová D, Stefanovic J (1983) Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone. J Hyg Epidemiol Microbiol Immunol 27:253–257PubMed
24.
Zurück zum Zitat Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I, Correia J, Barbosa P, Mendenca T, Vasconcelos C (2009) Linfopenia T CD4 no lúpus eritematoso sistémico. Acta Rheumatol Port 34:200–206 Ferreira S, Vasconcelos J, Marinho A, Farinha F, Almeida I, Correia J, Barbosa P, Mendenca T, Vasconcelos C (2009) Linfopenia T CD4 no lúpus eritematoso sistémico. Acta Rheumatol Port 34:200–206
Metadaten
Titel
Serum levels of selected chemokines in systemic lupus erythematosus patients
verfasst von
Eugeniusz Hrycek
Andrzej Franek
Edward Błaszczak
Justyna Dworak
Antoni Hrycek
Publikationsdatum
01.09.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 9/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2393-5

Weitere Artikel der Ausgabe 9/2013

Rheumatology International 9/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.